Morgan Stanley and Jefferies Financial Group raised their ratings and price objectives for PTC Therapeutics.
4 reports, 2 independent
Updated Jul 9
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley and Jefferies Financial Group raised their ratings and price objectives for PTC Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
PTC Therapeutics
pharmaceutical company
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
Jefferies Financial Group
American financial services company
Related events
- Morgan Stanley increased price target and rating for Omnicom Group.
- Morgan Stanley, Jefferies Financial Group, and Royal Bank of Canada issued rating and price target updates on September 14, 2026.
- Jefferies Financial Group began coverage, Morgan Stanley set a high price target, and Keefe, Bruyette & Woods increased price objectives, with MarketBeat reporting the average stock rating.
- Morgan Stanley issued a rating and price target for Trevi Therapeutics, Inc. on August 28, 2026.
- Bank of America, Morgan Stanley, and Lazard Asset Management LLC have raised ratings and increased institutional holdings in PTEN stock.